SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR KAMDHENU BUILDING, KOLKATA -700016 Email: shreeganeshbiotechindialtd@gmail.com Website: www.shreeganeshbiotech.com

Date: 13.02.2024

To,

To,

To,

Listing Department,

The Secretary,

Head - Listing

BSE Limited,

The Calcutta Stock

Metropolitan Stock Exchange of

P J Tower, Dalal

Exchange Ltd,

India Limited

Street

7, Lyons Range,

Vibgyor Towers, 4th floor, Plot No

Mumbai-400001

Kolkata - 700001

C 62, Opp. Trident Hotel Bandra

Kurla Complex, Bandra (E),

Mumbai - 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREEGANES

Dear Sir / Madam,

Sub: Un-Audited Financial Result quarter ended on 31st December 2023 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015.

Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company met in their meeting held on today i.e. **Tuesday 13th February 2024.**

1.) Considered and approved Un-audited financial results for the quarter ended as on 31st December 2023.

The meeting commenced at 04:00 P.M. and concluded at 04:30.P.M.

Kindly take the same on your record and oblige.

Thanking You

BIO-TECH (INDIA) LIMITED

Wholetime Director DIN: 08483544

Shree Ganesh Biotech (India) Limited

CIN: L70101WB1982PLC121196

Reg. Office Address: 126, 3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016

Email: shreeganeshbiotechindialtd@gmail.com

	-	Statement of Standalone Financ	iai Kesuits ioi	the quarter er	ided on Decem		In Lakh except	ner share data)
Particulars	Particulars			Quarter Ended			Nine Months Ended	
Date of start of reporting period D-10-2023 D-10-2023 D-10-2022 D-10-2023 D-10-2022 D-10-2023 D-10-2022 D-10-2023 D-10-2022 D-10-2023 D-10-2022 D-10-2023 D-10-2023 D-10-2022 D-10-2023 D-10-2022 D-10-2023 D-10-2022 D-10-2023 D-10-2022 D-10-2023 D-10-2022 D-10-2023 D-10-2022 D-10-2023 D-10					31-12-2022		31-12-2022	Year Ended 31-03-2023
Date of end of reporting period 31-12-2023 31-09-2023 31-12-20	-	Date of start of reporting period					01-04-2022	01-04-2022
C	-						31-12-2022	31-03-2023
Nature of report standalone or consolidated Standalone Standalone Standalone I	-			AND ADDRESS OF THE OWNER, THE OWN			Unaudited	Audited
Revenue From Operations	-						Standalone	Standalone
Net sales or Revenue from Operations	_		Standarone	Standarone	Standarone	Standarone	Stanuarone	Standarone
Other Income			412.25	411.81	1 207 30	1 640 44	5,447.70	6,245.45
Total Income (I+II)			the same of the sa			1,045.44	(1.94)	56.49
IV Expenses						1 649 44	5,445.76	6,301.94
(a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefit expense (d) Employee benefit expense (e) Finance Costs (f) Depreciation and amortisation expense (g) Other Expenses (g) Other Expenses (g) Other Expenses (h) Perfectiation and amortisation expense (g) Other Expenses (g) Other Expenses (h) Honge expenses (h) Honge expense (h) Honge expenses (h) Honge expense expenses (h) Honge expenses (h)			TILLES	411.01	1,207.70	2,043.44	3,443.70	0,301.34
(b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefit expense			397.50	397.07	1 174 60	1 590 41	5,153.04	5,962.93
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade and sto							3,133.04	3,302.33
and stock-in-trade							-	
(d) Employee benefit expense			-					
(e) Finance Costs (f) Depreciation and amortisation expense (g) Other Expenses Total expenses (IV) Profit/(loss) before exceptional items and tax (III-IV) Exceptional items Profit (loss) after exceptional items and before Tax (V-VI) Exceptional items Profit (loss) after exceptional items and before Tax (V-VI) Exceptional items Profit (loss) after exceptional items and before Tax (V-VI) Exceptional items Profit (loss) after exceptional items and before Tax (V-VI) Exceptional items Profit (loss) after exceptional items and before Tax (V-VI) Exceptional items Profit (loss) after exceptional items and before Tax (V-VI) Exceptional items			2 10	2 02	2 92	10.71	15.68	21.77
(f) Depreciation and amortisation expense				3.93	3.03	10.71	13.00	21.//
Other Expenses 2.89 3.29 2.04 17.18 Total expenses (IV) 403.56 404.29 1,180.47 1,618.30 V Profit/(loss) before exceptional items and tax (III-IV) 8.69 7.52 26.93 31.14 VI Exceptional items								0.06
Total expenses (IV)				2 20	2.04	1710	15.26	45.76
V Profit/(loss) before exceptional items and tax (III-IV) 8.69 7.52 26.93 31.14 VI Exceptional items								
VII Exceptional items VII Profit (loss) after exceptional items and before Tax (V-VI) Rofit (loss) after exceptional items and before Tax (V-VI) VIII Tax Expense (a) Current Tax (b) (Less): MAT Credit (c) Current Tax Expense Relating to Prior years (d) Deferred Tax (Asset)/Liabillities IX Profit (Loss) after Tax for the period (VII-VIII) X Other Comprehensive Income a. i). Items that will not be reclassified to profit or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassified to profit or loss Total Comprehensive income ITOTAL Comprehensive income ITOTAL Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Pace value of equity share capital (Per Share) INDICATE SAGES (Asset) 1.14 1.14 1.14 1.14 1.15 1.15 1.14 1.15 1	1	1 expenses (1V)	405.30	404.29	1,100.47	1,010.30	5,183.98	6,030.52
VIII Profit (loss) after exceptional items and before Tax (V-VI) 8.69 7.52 26.93 31.14 VIII Tax Expense (a) Current Tax (b) (Less):- MAT Credit (c) Current Tax Expense Relating to Prior years (d) Deferred Tax (Asset)/Liabilities IX Profit (Loss) after Tax for the period (VII-VIII) 8.69 7.52 26.93 31.14 X Other Comprehensive Income a. i). Items that will not be reclassified to profit or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassified to profit or loss Total Comprehensive income XI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Paid-up equity share capital (Per Share) 1.00 1.00 1.00 1.00 XIII Other Equity			NAME OF TAXABLE PARTY.	TOTAL CONTRACTOR	55,000		261.78	271.42
Tax Expense	p	ptional items	-	-	-1	-	-	-
(a) Current Tax (b) (Less):- MAT Credit (c) Current Tax Expense Relating to Prior years (d) Deferred Tax (Asset)/Liabilities IX Profit (Loss) after Tax for the period (VII-VIII) X Other Comprehensive Income a. i). Items that will not be reclassified to profit or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassified to profit or loss ii). Income tax relating to items that will be reclassified to profit or loss Total Comprehensive income XI Potal Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Paid-up equity share capital Paid-up equity share capital Paid-up equity share capital (Per Share) I Dotal Comprehensive income 1.00 I Dotal Comprehensive income 2.00 I Dotal Comprehensive income 3.986.24 I Dotal Compr	it	it (loss) after exceptional items and before Tax (V-VI)	8.69	7.52	26.93	31.14	261.78	271.42
(b) (Less):- MAT Credit (c) Current Tax Expense Relating to Prior years (d) Deferred Tax (Asset)/Liabilities IX Profit (Loss) after Tax for the period (VII-VIII) 8.69 7.52 26.93 31.14 X Other Comprehensive Income a. i). Items that will not be reclassified to profit or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassified to profit or loss ii). Income tax relating to items that will be reclassified to profit or loss Total Comprehensive income Total Comprehensive income Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Paid-up equity share capital Face value of equity share capital (Per Share) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.0	E	Expense			- + · · ·			67.55
Current Tax Expense Relating to Prior years Current Tax Expense Relating to Prior years Current Tax (Asset)/Liabilities Current Tax (A			-					67.55
(d) Deferred Tax (Asset)/Liabilities IX Profit (Loss) after Tax for the period (VII-VIII) 8.69 7.52 26.93 31.14 X Other Comprehensive Income a. i). Items that will not be reclassified to profit or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassifed to profit or loss ii). Income tax relating to items that will be reclassifed to profit or loss Total Comprehensive income XI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Face value of equity share capital (Per Share) XIII Other Equity			-					
IX Profit (Loss) after Tax for the period (VII-VIII) X Other Comprehensive Income a. i). Items that will not be reclassified to profit or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassified to profit or loss ii). Income tax relating to items that will be reclassified to profit or loss ii). Income tax relating to items that will be reclassified to profit or loss Total Comprehensive income Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Other Equity	e	ent Tax Expense Relating to Prior years						-
X Other Comprehensive Income a. i). Items that will not be reclassified to profit or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassified to profit or loss ii). Income tax relating to items that will be reclassified to profit or loss Total Comprehensive income XI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Paid-up equity share capital Face value of equity share capital (Per Share) 1.00 1.00 1.00 1.00 XIII Other Equity	r	rred Tax (Asset)/Liabilities	-					
X Other Comprehensive Income a. i). Items that will not be reclassified to profit or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassified to profit or loss ii). Income tax relating to items that will be reclassified to profit or loss Total Comprehensive income XI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Paid-up equity share capital Face value of equity share capital (Per Share) 1.00 1.00 1.00 1.00 XIII Other Equity	it	it (Loss) after Tax for the period (VII-VIII)	8.69	7.52	26.93	31.14	261.78	203.87
a. i). Items that will not be reclassified to profit or loss ii). Income tax relating to items that will not be reclassified to profit or loss b. i). Item that will be reclassifed to profit or loss ii). Income tax relating to items that will be reclassifed to profit or loss Total Comprehensive income XI Period and Other comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) 8.69 7.52 26.93 31.14 XII Details of equity share capital Paid-up equity share capital Paid-up equity share capital Face value of equity share capital (Per Share) 1.00 1.00 1.00 1.00 1.00 1.00 1.00								
to profit or loss b. i). Item that will be reclassifed to profit or loss ii). Income tax relating to items that will be reclassifed to profit or loss Total Comprehensive income XI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) 8.69 7.52 26.93 31.14 XII Details of equity share capital Paid-up equity share capital Paid-up equity share capital Face value of equity share capital (Per Share) 1.00 1.00 1.00 1.00 XIII Other Equity			-	-			-	
b. i). Item that will be reclassifed to profit or loss ii). Income tax relating to items that will be reclassifed to profit or loss Total Comprehensive income XI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) 8.69 7.52 26.93 31.14 XII Details of equity share capital Paid-up equity share capital Face value of equity share capital (Per Share) 1.00 1.00 1.00 1.00 XIII Other Equity								-
ii). Income tax relating to items that will be reclassifed to profit or loss Total Comprehensive income Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Face value of equity share capital (Per Share) XIII Other Equity							-	
profit or loss Total Comprehensive income XI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) XII Details of equity share capital Paid-up equity share capital Face value of equity share capital (Per Share) XIII Other Equity Paid-up equity share capital (Per Share) Total Comprehensive income Sample						-		
Total Comprehensive income				-	-	-		
Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV) 8.69 7.52 26.93 31.14					100 mg			
Period and Other comprehensive income (XIV+XV) 3.09 7.32 26.93 31.14	ä	1 Comprehensive medite		and the second				
Paid-up equity share capital 3,986.24 3,986.24 3,986.24 3,986.24 3,986.24 3,986.24 5 5 5 5 5 5 5 5 5			8.69	7.52	26.93	31.14	261.78	203.87
Paid-up equity share capital 3,986.24 3,986.24 3,986.24 3,986.24 3,986.24 Face value of equity share capital (Per Share) 1.00	-	ila of a miles above accided						
Face value of equity share capital (Per Share) 1.00 1.00 1.00 1.00 1.00 1.00 1.00			2 086 24	2 096 24	2 096 24	2 086 24	3,986.24	3,986.24
XIII Other Equity							1.00	1.00
			1.00	1.00	1.00	1.00	1.00	2,249,43
			SUI NECESSARIA	E CONTRACTOR OF THE CONTRACTOR		V-0.00		4,449.43
	_							
(a) Earnings per share (not annualised for quarter ended)	i	ings per share (not annualised for quarter ended)						
Basic earnings (loss) per share from continuing operation 0.00 0.00 0.01 0.01	C	earnings (loss) per share from continuing operation	0.00	0.00	0.01	0.01	0.07	0.05

0.00

Diluted earnings (loss) per share from continuing operation



0.00

0.01

0.01

0.07

0.05

Shree Ganesh Biotech (India) Limited

CIN: L70101WB1982PLC121196

Reg. Office Address: 126, 3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016

Email: shreeganeshbiotechindialtd@gmail.com

1	The above unaudited standalone financial results for the quarter ended December 31, 2022 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their respective meetings held on Febuary 13, 2024. The statutory auditors have carried out limited review of above result.
2	The unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) (Amendment Rules), 2016.
3	As per Indian Accounting Standard 108 on 'Operating Segment' (Ind AS 108), the company has only one reportable segment.
4	The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.
5	Earning Per Share (EPS) for current and previous periods are recalculated, as per the new Face Value of Rs. 1/- per share, consequent to the sub-division of Equity Shares.

For, Shree Ganesh Biotech (India) Limited

Date: 13th February, 2024

Provison for Taxation if any will be made at year end.

Notes on Financial Results:-

Place:- Kolkata

Wholetime Director DIN: 08483544

BIPIN & CO.

CHARTERED ACCOUNTANTS



CA. TEJAS PUROHIT F.C.A., DISA, M. Com. 98257 68699
CA. DHARIT K. SHAH F.C.A., LL.B., B. Com. 94273 41134
CA. AMIT D. SHAH F.C.A., D.T.P., B. Com. 94263 13900
CA. SURESH SISODIA F.C.A., A.C.S., LL.B. 98251 56037
CA. MOHIT ARORA A.C.A. 88796 29379

Limited Review Report

To
The Board of Directors of
SHREE GANESH BIO-TECH (INDIA) LIMITED
KOLKATA

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SHREE GANESH BIO-TECH (INDIA) LIMITED**("the Company"), for the Quarter ended on December 31, 2023 and year to date result for the period from 01 April, 2023 to 31 December, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bipin & Co.
Chartered Accountants

FRN: 101509 W

CA Amit Shah Partner M. No.: 126337

UDIN:. 24126337BKCXQA9171

Place: Vadodara Date: 13.02.2024

